4.5 Article

Vancomycin Hypersensitivity Reactions Documented in Electronic Health Records

Journal

Publisher

ELSEVIER
DOI: 10.1016/j.jaip.2020.09.027

Keywords

Vancomycin; Allergy; Phenotype; Hypersensitivity; Infusion reaction; Drug allergy label; Electronic health record; Red man syndrome; Drug reaction eosinophilia and systemic symptoms syndrome; Epidemiology

Funding

  1. National Institutes of Health (NIH)-National Institute of General Medical Sciences [T32GM066691]
  2. NIH-National Institute of Diabetes and Digestive and Kidney Diseases [5F30DK120160]
  3. NIH-National Institute of Allergy and Infectious Diseases (NIAID) [K01AI125631]
  4. American Academy of Allergy, Asthma, and Immunology (AAAAI) Foundation
  5. NIHNIAID [R01AI150295]
  6. Agency for Healthcare Research and Quality (AHRQ) [R01HS025375]
  7. Massachusetts General Hospital (MGH) Claflin Distinguished Scholar Award

Ask authors/readers for more resources

This study described the epidemiology of vancomycin hypersensitivity reactions documented in electronic health records, showing a wide range of reactions including common and severe reactions. The documentation of Red Man Syndrome was more likely for males and less likely for blacks, suggesting a demographic association.
BACKGROUND: Vancomycin, the most common antimicrobial used in US hospitals, can cause diverse adverse reactions, including hypersensitivity reactions (HSRs). Yet, little is known about vancomycin reactions documented in electronic health records. OBJECTIVE: To describe vancomycin HSR epidemiology from electronic health record allergy data. METHODS: This was a cross-sectional study of patients with 1 or more encounter from 2017 to 2019 and an electronic health record vancomycin drug allergy label (DAL) in 2 US health care systems. We determined prevalence and trends of vancomycin DALs and assessed active DALs by HSR phenotype determined from structured (coded) and unstructured (free-text) data using natural language processing. We investigated demographic associations with documentation of vancomycin red man syndrome (RMS). RESULTS: Among 4,490,618 patients, 14,426 (0.3%) had a vancomycin DAL with 18,761 documented reactions (2,248 [12.0%] free-text). Quarterly mean vancomycin DALs added were 253 +/- 12 and deleted were 12 +/- 2. Of 18,761 vancomycin HSRs, 7,903 (42.1%) were immediate phenotypes and 3,881 (20.7%) were delayed phenotypes. Common HSRs were rash (32% of HSRs) and RMS (16% of HSRs). Anaphylaxis was coded in 6% cases of HSRs. Drug reaction eosinophilia and systemic symptoms syndrome was the most common coded vancomycin severe cutaneous adverse reaction. RMS documentation was more likely for males (odds ratio, 1.30; 95% CI, 1.17-1.44) and less likely for blacks (odds ratio, 0.59; 95% CI, 0.47-0.75). CONCLUSIONS: Vancomycin causes diverse adverse reactions, including common (eg, RMS) and severe (eg, drug reaction eosinophilia and systemic symptoms syndrome) reactions entered as DAL free-text. Anaphylaxis comprised 6% of documented vancomycin HSRs, although true vancomycin IgEmediated reactions are exceedingly rare. Improving vancomycin DAL documentation requires more coded entry options, including a coded entry for RMS. (C) 2020 American Academy of Allergy, Asthma & Immunology

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available